Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH63500D
  • |
  • Pages: 31
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Pharmaxis Ltd (Pharmaxis) is a pharmaceutical research company that develops and commercialize healthcare products. The company offers products such as aridol which identify twitchy and assist in diagnosing and managing asthma, and bronchitol which restores normal lung hydration, improves lung function and relieves the mucus burden in the lungs of patients. Its products pipeline includes orbital dry powder inhaler, PXS-4728A, LOXL-2 and ASM8. The company offers solutions for cystic fibrosis, bronchiectasis, asthma and chronic obstructive pulmonary disease, and inflammatory and fibrotic diseases such as nonalcoholic steatohepatitis and pulmonary fibrosis, among others. Pharmaxis is headquartered in Sydney, New South Wales, Australia.

Pharmaxis Ltd (PXS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Pharmaxis Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Pharmaxis Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 11

Pharmaxis Expands Agreement with Synairgen 12

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 13

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici for Bronchitol in US 14

Pharmaxis Enters Into Distribution Agreement With PharmaSwiss For Bronchitol 15

Equity Offering 16

Pharmaxis to Raise USD17.7 Million in Private Placement of Shares 16

Pharmaxis Announces Second Tranche Of Private Placement Of Shares For USD 20 Million 18

Asset Transactions 19

Boehringer Ingelheim Acquires Anti-Inflammatory Drug Candidate from Pharmaxis 19

Pharmaxis Ltd-Key Competitors 21

Pharmaxis Ltd-Key Employees 22

Pharmaxis Ltd-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

Sep 27, 2017: Synairgen: Interim results for the six months ended 30 June 2017 24

Corporate Communications 25

Oct 19, 2017: Pharmaxis Strengthens Drug Discovery Capability as its Technology Platform Continues to Deliver 25

Jun 07, 2017: Pharmaxis Appoints Former Head of Global Research at Merck to Board of Directors 26

Product News 27

Mar 10, 2017: Synairgen: Additional Positive Data in Lung Fibrosis 27

Clinical Trials 28

Jun 14, 2018: Pharmaxis "Best in Class" LOXL2 Program Attracts Strong Pharma Interest as it Enters Final Stages of Phase 1 Trials 28

Jun 14, 2018: Pharmaxis 'Best In Class' LOXL2 Program Attracts Strong Pharma Interest As It Enters Final Stage Of Phase 1 Trials 29

Sep 06, 2017: Pharmaxis Announces Anti Fibrotic LOXL2 Program Clears Preclinical Development And Set To Commence Phase 1 Trials 30

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31

List of Figures

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Pharmaxis Ltd, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Pharmaxis Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Pharmaxis Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Pharmaxis Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 11

Pharmaxis Expands Agreement with Synairgen 12

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 13

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici for Bronchitol in US 14

Pharmaxis Enters Into Distribution Agreement With PharmaSwiss For Bronchitol 15

Pharmaxis to Raise USD17.7 Million in Private Placement of Shares 16

Pharmaxis Announces Second Tranche Of Private Placement Of Shares For USD 20 Million 18

Boehringer Ingelheim Acquires Anti-Inflammatory Drug Candidate from Pharmaxis 19

Pharmaxis Ltd, Key Competitors 21

Pharmaxis Ltd, Key Employees 22

Pharmaxis Ltd, Subsidiaries 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Pharmaxis Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17815
Site License
USD 500 INR 35630
Corporate User License
USD 750 INR 53445

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com